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Contraception 86 (2012) 594–595Letters to the EditorComment on research article: “Co-prescription of
Antiepileptic Drugs and Contraceptives”
To the Editor:
The issue raised by Wang et al. [1] is of vital importance
in avoiding unintended pregnancies and highlights the need
for initial and continuing updating for prescribers of
antiepileptic drugs and contraception.
In the UK, there is only one combined oral contraceptive
pill containing 50 mcg of an estrogen (Norinyl-1). This
preparation contains mestranol, a pro-drug partly metabo-
lized to ethinylestradiol, which means that the potency of
Norinyl-1 is roughly equivalent to that of a 30-mcg
ethinylestradiol pill. It is recommended by the Clinical
Effectiveness Unit of the Faculty of Sexual and Reproduc-
tive Healthcare of the Royal College of Obstetricians and
Gynaecologists [2] that to achieve adequate circulating
levels of ethinylestradiol, women taking enzyme-inducing
drugs should be given one tablet of a 20-mcg plus one 30-
mcg preparation, or two 30-mcg pills together daily (outside
the product license), together with shortening the pill-free
interval to 4 days or using extended regimens. Therefore,
depending on the level of detail, the UK prescribing data do
not always allow accurate determination of the dose actually
taken. We wonder if this practice is also common in the
Netherlands and if it was possible to identify this amongst
the data for prescription of low-dose pills?
There seems to be no distinction in the paper between the
different types of oral contraceptive or other methods of
combined hormonal contraception such as the patch or
vaginal ring. Combined hormonal oral preparations are the
focus of the paper. There is arguably even greater concern
about the situation for progestogen-only oral contraception
and subdermal progestogen-only implants, where advice in
the UK is to use alternative methods when enzyme-inducing
medication is co-administered.
Lamotrigine, whilst listed as enzyme inducing, does not
appear to have any effect on contraceptive effectiveness, but
is not recommended to be used together with combined
hormonal contraception as its levels may ﬂuctuate on
initiating and discontinuing the contraceptive during the
hormone-free week, leading to reduction in seizure control
and drug toxicity [2].0010-7824/$ – see front matter © 2012 Elsevier Inc. All rights reserved.Alyson Elliman
Croydon Health Services NHS Trust
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Reply to the Letter to the Editor on “Co-prescription of
Antiepileptic Drugs and Contraceptives”
To the Editor:
We appreciate the valuable comments by Elliman and
Melvin, especially their reference to the Faculty of Sexual
and Reproductive Healthcare Clinical Guidance of 2011 and
update of 2012 [1], which were not yet available to us at the
time of the submission of our manuscript.
Our analysis was based on pharmacy dispensing data over
the year 2006; at that time, there was no guideline to pre-
scribe two low-dose estrogen contraceptive pills to women
using enzyme-inducing antiepileptic drugs, and this kind of
prescription method was not practiced. We have checked the
prescription database of the year 2006 and found only one
595Letters to the Editor / Contraception 86 (2012) 594–595woman who was dispensed a combination two low-dose oral
estrogen contraceptives.
We agree that progestogen-only oral contraception is of
concern among enzyme-inducing antiepileptic drug users.
This practice is rare in the Netherlands; in our 2006 phar-
macy dispensing database, we found that less than 0.5% of
all women of fertile age (i.e., irrespective of concomitant use
of any medication) were on progestogen-only oral contra-
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